Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis

Fig. 3

SRI4 response (in patients with SELENA-SLEDAI ≥ 4 at baseline) by visit. BLyS B lymphocyte stimulator, IFN interferon, IFN-1 type 1 IFN-inducible gene signature, mRNA messenger ribonucleic acid, SELENA-SLEDAI Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index, SLE systemic lupus erythematosus, SRI Systemic Lupus Erythematosus Responder Index

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us